Courageous Discourse™ with Dr. Peter McCullough & John Leake

Share this post

Courageous Discourse™ with Dr. Peter McCullough & John Leake
Courageous Discourse™ with Dr. Peter McCullough & John Leake
Moderna mRNA RSV Trial Finds Absolute Risk Reduction <1%
Copy link
Facebook
Email
Notes
More

Moderna mRNA RSV Trial Finds Absolute Risk Reduction <1%

ConquerRSV Study Reports Adult RSV Very Rare--Not Worth Risk of Genetic mRNA Vaccination

Dec 19, 2023
241

Share this post

Courageous Discourse™ with Dr. Peter McCullough & John Leake
Courageous Discourse™ with Dr. Peter McCullough & John Leake
Moderna mRNA RSV Trial Finds Absolute Risk Reduction <1%
Copy link
Facebook
Email
Notes
More
20
29
Share
Article voiceover
1×
0:00
-2:40
Audio playback is not supported on your browser. Please upgrade.

By Peter A. McCullough, MD, MPH

Rare illnesses which are mild should not be the target for mass vaccination. Because so few people get the problem, and in the case of respiratory syncytial virus, the illness is so mild and easily treatable with albuterol and budesonide nebulizers, it is hard to make the case for mass vaccination with a novel mRNA platform.

Nevertheless, Moderna conducted a large randomized trial in adults at “high-risk” for RSV reporting only 20 cases (with three symptoms such as nasal congestion, cough, fever) out of 35,541 subjects (rate=.056%). Safety grade 3 or higher events at 28 days were reported in 4.0% of Moderna and 2.9% of placebo patients, respectively. The most common solicited systemic adverse reactions were fatigue, headache, myalgia, and arthralgia. There was one case of Moderna mRNA pericarditis at 42 days. The short-term vaccine efficacy was 82.4%.

Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Rämet M, Pérez-Breva L, Falsey AR, Walsh EE, Dhar R, Wilson L, Du J, Ghaswalla P, Kapoor A, Lan L, Mehta S, Mithani R, Panozzo CA, Simorellis AK, Kuter BJ, Schödel F, Huang W, Reuter C, Slobod K, Stoszek SK, Shaw CA, Miller JM, Das R, Chen GL; ConquerRSV Study Group. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079. PMID: 38091530.

I do not recommend adult RSV vaccination of any type since this is a very mild and rare infection in adults indistinguishable from the common cold. One serious side effect should be enough to kill interest in more clinical development.

Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth.

Courageous Discourse™ with Dr. Peter McCullough & John Leake is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

Peter A. McCullough, MD, MPH

President, McCullough Foundation

www.mcculloughfnd.org

Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Rämet M, Pérez-Breva L, Falsey AR, Walsh EE, Dhar R, Wilson L, Du J, Ghaswalla P, Kapoor A, Lan L, Mehta S, Mithani R, Panozzo CA, Simorellis AK, Kuter BJ, Schödel F, Huang W, Reuter C, Slobod K, Stoszek SK, Shaw CA, Miller JM, Das R, Chen GL; ConquerRSV Study Group. Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults. N Engl J Med. 2023 Dec 14;389(24):2233-2244. doi: 10.1056/NEJMoa2307079. PMID: 38091530.

241

Share this post

Courageous Discourse™ with Dr. Peter McCullough & John Leake
Courageous Discourse™ with Dr. Peter McCullough & John Leake
Moderna mRNA RSV Trial Finds Absolute Risk Reduction <1%
Copy link
Facebook
Email
Notes
More
20
29
Share

Discussion about this post

Dr. Kevin Stillwagon
Dec 19, 2023

There are two RSV shots called vaccines currently approved by the FDA. One is AREXVY made by GSK and the other is ABRYSVO made by Pfizer. Both are traditional in the sense that they inject part of the RSV virus called the prefusion F glyocoprotein that is grown in chinese hamster ovaries. The idea is that by injecting a little bit of this antigen, the human immune system will build antibodies against the protein before the antigens start binding to human CX3CR1 receptors that exist on monocytes, macrophages, dendritic cells, some T-cell subsets, natural killer cells, and microglial cells before your immune system gets wrecked and your brain becomes inflamed.

But, Moderna has a better idea. They want to inject the message to have the cells of your body make tons of the RSV prefusion F glycoproteins. Not a little bit of them, TONS of them. What cells of your body will make them? Any cell that the lipid nanoparticle that contains the message will bind to, and just like the covid shot, this will be any and all cells. Your immune system will attack and destroy cells that are making these foreign proteins. This is a really bad idea. But, the FDA will approve it.

Expand full comment
Reply
Share
3 replies
TheWitness
Dec 19, 2023

Had family over this weekend after the death of my father-in-law last week and my sister-in-law was telling me that two boys from their Geneva, IL high school died in the last week due to aneurisms, and she shouted out it had to be that blanking vaccine. She and her family never wanted to take them, but they were forced to keep their jobs and three of her four boys were forced to in order to continue on in sports. Now she's worried. I send her your spike detox. I hope she goes with it for her three boys who were jabbed. Of course I worry about them and their boys too as does my wife. It just makes us sick.

Expand full comment
Reply
Share
18 more comments...

No posts

Ready for more?

© 2025 Peter McCullough MD MPH
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More